Liver regeneration

Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease

Retrieved on: 
Monday, April 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, USD, Cirrhosis, Genomics, CLD, Liver disease, Boehringer Ingelheim, Chronic liver disease, Machine learning, The Gentle Touch, RNA, Partnership, Liver regeneration, Senior, Patient, Liver failure, DSM-IV codes, Disease, CRM, Boehringer, MASH, Outsourcing, Copper

Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Key Points: 
  • Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
  • Boehringer Ingelheim aims to develop new treatments modulating innovative regenerative targets with the potential to enhance the liver’s self-repair capabilities to prevent or reverse disease progression.
  • It builds on Ochre Bio’s leading capabilities to leverage human data and disease models to accelerate the discovery and validation of novel liver disease targets.
  • “Ochre Bio brings to the table unique and exciting capabilities in liver disease research.

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, April 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, April 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Crew-7 Astronauts Return to Earth After Nearly 200 Days Conducting Critical Science in Space

Retrieved on: 
Tuesday, March 12, 2024
SpaceX Crew-7, Emory University, Commercial Crew Program, European Space Agency, ZBLAN, JAXA, Biotechnology, Redwire, Growth, Medication, SPACE, Exploration, Patient, ISS National Lab, Research, University, Boeing, International Space Station, Bacteria, Virus, Software, Ageing, Glass, Liver regeneration, ProLiant, NASA, System, ISS, Therapy, SpaceX, HPE

Results from this project, funded by the U.S. National Science Foundation, could help boost our understanding of aging and its effects on disease mechanisms.

Key Points: 
  • Results from this project, funded by the U.S. National Science Foundation, could help boost our understanding of aging and its effects on disease mechanisms.
  • If successful, the powdered protein could help significantly reduce the mass of materials traveling to the space station, allowing more manufacturing at a lower cost.
  • The crew also continued work on a Boeing-sponsored investigation to test the effectiveness and durability of an innovative antimicrobial coating in space.
  • Findings will help advance heart disease modeling and could lead to the development of new therapies for patients on Earth.

SpaceX Returns Vital Life Science Research Sponsored by the ISS National Lab

Retrieved on: 
Friday, December 22, 2023
International Space Station, University, Science, Dementia, ISS National Lab, DSM-IV codes, Immune system, ISS, SPACE, Research, Liver regeneration, Brain, Alzheimer's disease, NASA, NSF, 3D, UCSD, Ageing, Commerce, SpaceX, CRS, Growth, Patient, Spacecraft, Commercial Resupply Services, UCSF, Medical imaging

More than 30 payloads sponsored by the ISS National Laboratory® returned on this mission, many of which were life science investigations aimed at benefiting humanity by improving care for patients on Earth.

Key Points: 
  • More than 30 payloads sponsored by the ISS National Laboratory® returned on this mission, many of which were life science investigations aimed at benefiting humanity by improving care for patients on Earth.
  • An investigation from the University of California, San Francisco (UCSF) that was funded by the U.S. National Science Foundation (NSF) focused on aging and liver regeneration.
  • The ISS National Lab enables access and opportunity for researchers to leverage this unique orbiting outpost for the benefit of humanity and to enable commerce in space.
  • To learn more about ISS National Lab-sponsored investigations that flew on SpaceX CRS-29, please visit our launch page .

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, HCC, NSCLC, AACR, Rheumatism, American Association for the Study of Liver Diseases, OMEGA, IND, International, Therapy, Hepatology, Flagship Pioneering, Liver regeneration, G&A, Investigational New Drug, Conference, Palatine Nos. 1–8, 21, Fibrosis, Dive (Belgian band), MYC, Hepatitis, R, Pharmacokinetics, Acute respiratory distress syndrome, Omega, Epigenomics, Lung, Tissue, Annual report, Messenger, LNP, Institutional review board, Inflammation, Lung cancer, Hepatocellular carcinoma, Cancer, Patient, Gene expression, AASLD, Management, Pharmaceutical industry, Vaccine, Dietary supplement

As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.

Key Points: 
  • As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
  • Research and development (R&D) expenses for the third quarter of 2023 were $16.5 million, compared to $20.7 million for the third quarter of 2022.
  • General and administrative (G&A) expenses for the third quarter of 2023 were $7.9 million, compared to $5.2 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $22.2 million, compared to $25.8 million for the third quarter of 2022, driven predominantly by a decrease in R&D expenses.

Lerna Bio unveils its first-in-class solution to combat liver failure

Retrieved on: 
Monday, November 6, 2023
Chronic liver disease, Liver regeneration, Hepatology, Physician, Cirrhosis, Liver, Mortality, Liver transplantation, Liver disease, NASH, Risk, AASLD, Liver failure, Transplant, American Association for the Study of Liver Diseases, Patient, Fatty liver disease, Small RNA, Adviser, Dietary supplement, Biology, Quartz

Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting in Boston organized by American Association for the Study of Liver Diseases (AASLD) from November 10th to 14th.

Key Points: 
  • Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting in Boston organized by American Association for the Study of Liver Diseases (AASLD) from November 10th to 14th.
  • By targeting liver regeneration, LR1 provides a novel mechanism and innovative solution for patients at risk of liver failure.
  • Every year, over 2 million lives succumb to liver failure due to liver cirrhosis resulting from chronic liver diseases, making it a leading cause of mortality worldwide.
  • Commenting on the potential of LR1, Ms. Kathy He, CEO of Lerna Bio, enthused, "Leveraging liver's innate regenerative capacity to combat liver diseases has been a longstanding aspiration for liver researchers.